[
  {
    "ts": null,
    "headline": "Pfizer Inc (PFE) Rating Steady Amid Neutral Market Outlook and Pipeline Progress",
    "summary": "We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Pfizer Inc tops our list for being one of the most undervalued pharmaceutical stocks. On Friday, December 12, 2025, The Fly reported that Morgan Stanley maintained its Hold (Equal‑Weight) rating on PFE., while lowering the price target to $28 from […]",
    "url": "https://finnhub.io/api/news?id=d3b053fcbc581ae7402011a08016cee179e3aaeb0346f1aa61efe36ec19b2646",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766009280,
      "headline": "Pfizer Inc (PFE) Rating Steady Amid Neutral Market Outlook and Pipeline Progress",
      "id": 137817227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Pfizer Inc tops our list for being one of the most undervalued pharmaceutical stocks. On Friday, December 12, 2025, The Fly reported that Morgan Stanley maintained its Hold (Equal‑Weight) rating on PFE., while lowering the price target to $28 from […]",
      "url": "https://finnhub.io/api/news?id=d3b053fcbc581ae7402011a08016cee179e3aaeb0346f1aa61efe36ec19b2646"
    }
  },
  {
    "ts": null,
    "headline": "Lightning Round: I would buy M&T Bank tomorrow morning, says Jim Cramer",
    "summary": "'Mad Money' host Jim Cramer weighs in on stocks including: Pfizer, Elanco, Rocket Lab, Lithium Americas, Daktronics, Diageo, and more.",
    "url": "https://finnhub.io/api/news?id=2077d113e230be861aab2bb2200fbeca696fde48886cee98eb3b83f418b8251e",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766000549,
      "headline": "Lightning Round: I would buy M&T Bank tomorrow morning, says Jim Cramer",
      "id": 137823113,
      "image": "https://image.cnbcfm.com/api/v1/image/108243346-4ED4-REQ-121725-MMEBLOCKREDO.jpg?v=1766016748&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "'Mad Money' host Jim Cramer weighs in on stocks including: Pfizer, Elanco, Rocket Lab, Lithium Americas, Daktronics, Diageo, and more.",
      "url": "https://finnhub.io/api/news?id=2077d113e230be861aab2bb2200fbeca696fde48886cee98eb3b83f418b8251e"
    }
  },
  {
    "ts": null,
    "headline": "If I Could Only Buy and Hold a Single Stock, This Would Be It",
    "summary": "Pfizer's shares look attractive to investors willing to show patience.",
    "url": "https://finnhub.io/api/news?id=e677c8d78ee252896ecc1609a5730d70fdc32e6d0c4f48e5415b11e5c14b6abb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765991220,
      "headline": "If I Could Only Buy and Hold a Single Stock, This Would Be It",
      "id": 137817228,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's shares look attractive to investors willing to show patience.",
      "url": "https://finnhub.io/api/news?id=e677c8d78ee252896ecc1609a5730d70fdc32e6d0c4f48e5415b11e5c14b6abb"
    }
  },
  {
    "ts": null,
    "headline": "CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?",
    "summary": "CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.",
    "url": "https://finnhub.io/api/news?id=09f46cbdadf334a89b4243a86e9b3151556d8288986c2dc1d4f7cf9223d856dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765988760,
      "headline": "CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?",
      "id": 137817229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.",
      "url": "https://finnhub.io/api/news?id=09f46cbdadf334a89b4243a86e9b3151556d8288986c2dc1d4f7cf9223d856dd"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?",
    "summary": "PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.",
    "url": "https://finnhub.io/api/news?id=d45dd8a91341fb8f2bd6462374986bfea7a1b9580429d10e83422a4f7e3fee7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765983540,
      "headline": "Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?",
      "id": 137816781,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.",
      "url": "https://finnhub.io/api/news?id=d45dd8a91341fb8f2bd6462374986bfea7a1b9580429d10e83422a4f7e3fee7c"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Dec 17, 2025",
    "summary": "Companies in The News Are: PFE,KHC,F,PYPL",
    "url": "https://finnhub.io/api/news?id=1ddec35f738cd56827c2c3921f15f68ae167bc0ef7eab361e5944412c87f1cf4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765983060,
      "headline": "Company News for Dec 17, 2025",
      "id": 137817231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Companies in The News Are: PFE,KHC,F,PYPL",
      "url": "https://finnhub.io/api/news?id=1ddec35f738cd56827c2c3921f15f68ae167bc0ef7eab361e5944412c87f1cf4"
    }
  },
  {
    "ts": null,
    "headline": "The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now",
    "summary": "It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.",
    "url": "https://finnhub.io/api/news?id=06f7a6a5736ea3dcfc0cfc65be9da91695de8240065b8d8cbd59ba0a004083c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765978500,
      "headline": "The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now",
      "id": 137816783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.",
      "url": "https://finnhub.io/api/news?id=06f7a6a5736ea3dcfc0cfc65be9da91695de8240065b8d8cbd59ba0a004083c8"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Gain Pre-Bell as Traders Parse Latest Employment Data",
    "summary": "The main US stock measures were tracking in the green in Wednesday's premarket activity as traders d",
    "url": "https://finnhub.io/api/news?id=5a781304b04dd963d3f7984fddf11fce3c97bd4704a957728e7b6107dec4f439",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765974513,
      "headline": "Stocks Gain Pre-Bell as Traders Parse Latest Employment Data",
      "id": 137817233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The main US stock measures were tracking in the green in Wednesday's premarket activity as traders d",
      "url": "https://finnhub.io/api/news?id=5a781304b04dd963d3f7984fddf11fce3c97bd4704a957728e7b6107dec4f439"
    }
  },
  {
    "ts": null,
    "headline": "PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility",
    "summary": "Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor. This pivotal study is evaluating the combination as neoadjuvant and adjuvant treatment (before and after surgery) vers",
    "url": "https://finnhub.io/api/news?id=017b6a36a89271418e7cbd19230a19df57fa39129603f9281b10cac9d5b50b41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765971900,
      "headline": "PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility",
      "id": 137817234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor. This pivotal study is evaluating the combination as neoadjuvant and adjuvant treatment (before and after surgery) vers",
      "url": "https://finnhub.io/api/news?id=017b6a36a89271418e7cbd19230a19df57fa39129603f9281b10cac9d5b50b41"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Ignoring The Dead Cat Bounce",
    "summary": "Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield. Read more on PFE stock here.",
    "url": "https://finnhub.io/api/news?id=ee908d730f07e7263724712cb6a293ef5b083631785e395002a8e01a4b385bf6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765971005,
      "headline": "Pfizer: Ignoring The Dead Cat Bounce",
      "id": 137811899,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. is rated a Hold due to structural challenges despite recent 12% total return and compelling 6.7% dividend yield. Read more on PFE stock here.",
      "url": "https://finnhub.io/api/news?id=ee908d730f07e7263724712cb6a293ef5b083631785e395002a8e01a4b385bf6"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: 2026 Feels Like Another Lost Year After Yesterday's Guidance Update",
    "summary": "Explore Pfizer Inc.âs 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click for this updated look at PFE stock.",
    "url": "https://finnhub.io/api/news?id=f210ee2510fa5c3fc8ffc1638c7de053577f615cd92f45a13df4b3d3a5358541",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765970827,
      "headline": "Pfizer: 2026 Feels Like Another Lost Year After Yesterday's Guidance Update",
      "id": 137811901,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2185235471/image_2185235471.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Explore Pfizer Inc.âs 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click for this updated look at PFE stock.",
      "url": "https://finnhub.io/api/news?id=f210ee2510fa5c3fc8ffc1638c7de053577f615cd92f45a13df4b3d3a5358541"
    }
  },
  {
    "ts": null,
    "headline": "Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic",
    "summary": "COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne Louise Eberhard as new Chair of the Board of Directors, and in accordance with the Company’s Articles of Association, the Board has convened and has appointed Ms. Heidi Hunter as new Vice Chair. Ms. Hunter has been a member of the board since 2023. She has over 25 years of industry experience, working across the pharmaceutical value chain, from clinical and comm",
    "url": "https://finnhub.io/api/news?id=f40f372d530a6273e58c086844f2ae9d33bcc6a1ca5b9a46519b452a5fe8c436",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765956600,
      "headline": "Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic",
      "id": 137816807,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne Louise Eberhard as new Chair of the Board of Directors, and in accordance with the Company’s Articles of Association, the Board has convened and has appointed Ms. Heidi Hunter as new Vice Chair. Ms. Hunter has been a member of the board since 2023. She has over 25 years of industry experience, working across the pharmaceutical value chain, from clinical and comm",
      "url": "https://finnhub.io/api/news?id=f40f372d530a6273e58c086844f2ae9d33bcc6a1ca5b9a46519b452a5fe8c436"
    }
  }
]